EU endorses wider use of AstraZeneca cancer drug
29th Apr 2019 07:30
(Sharecast News) - AstraZeneca's ovarian cancer drug Lynparza on Monday received an endorsement from the European Medicines Agency, where a committee approved it to be used as a first-line maintenance treatment.
Read moreAstraZeneca sees product sales rise 10pc in first quarter
26th Apr 2019 07:23
(Sharecast News) - AstraZeneca reported a 10% increase in its product sales in its first quarter on Friday, or 14% at constant exchange rates, to $5.47bn.
Read moreFriday preview: US Q1 GDP, RBS in focus
25th Apr 2019 14:44
(Sharecast News) - Barring surprises, the market spotlight at the end of the week will continue to be on the States, where the Department of Commerce is expected to publish a preliminary reading on first quarter GDP (consensus: 1.8%).
Read moreThursday broker round-up
11th Apr 2019 11:58
(Sharecast News) - Ocado: HSBC downgrades to reduce with a target price of 900p.
Read moreWednesday broker round-up
10th Apr 2019 13:02
(Sharecast News) - Glencore: RBC Capital Markets downgrades to sector perform with a target price of 330p.
Read moreAstraZeneca confirms new EU approval for 'Lynparza'
10th Apr 2019 07:29
(Sharecast News) - AstraZeneca and its partner Merck & Co announced on Wednesday that the European Commission has approved 'Lynparza' (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1 and 2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.
Read moreFriday broker round-up
5th Apr 2019 12:53
(Sharecast News) - Purplebricks: Berenberg downgrades to sell with a target price of 80p.
Read moreTuesday broker round-up
2nd Apr 2019 12:14
(Sharecast News) - easyJet: Berenberg upgrades to hold with a target price of 1,040p.
Read moreLondon open: Stocks buoyed by China factory PMI, US-China trade news
1st Apr 2019 08:35
(Sharecast News) - Stocks are kicking-off the new quarter on the front foot, helped by stronger-than-expected economic data out of the People's Republic of China and further positive news on the state of US-China trade talks.
Read moreAstraZeneca gets 'breakthrough' status for selumetinib
1st Apr 2019 07:29
(Sharecast News) - AstraZeneca announced on Monday that the US Food and Drug Administration (FDA) has granted 'Breakthrough Therapy Designation' for the MEK 1/2 inhibitor and potential new medicine selumetinib, which it is developing in partnership with Merck & Co.
Read moreAstraZeneca to raise ?2.7bn for cancer collab, bond repayment
29th Mar 2019 08:03
(Sharecast News) - AstraZeneca plans to raise $3.5bn (£2.7bn) in a share placing to fund a new cancer drug collaboration with Japan's Daiichi Sankyo and repay some of its bonds.
Read moreMonday broker round-up
18th Mar 2019 13:37
(Sharecast News) - IWG: RBC Capital Markets upgrades to sector perform with a target price of 260p.
Read moreFDA grants orphan drug designation to AstraZeneca's 'saracatinib'
18th Mar 2019 08:07
(Sharecast News) - AstraZeneca announced on Monday that the US Food and Drug Administration (FDA) has granted 'orphan drug designation' for 'saracatinib' - a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
Read moreTobacco stocks rise after FDA boss Gottlieb quits
6th Mar 2019 09:20
(Sharecast News) - Shares in tobacco companies rose on Wednesday after America's chief drug and tobacco regulator unexpectedly resigned overnight.
Read moreWednesday broker round-up
27th Feb 2019 13:13
(Sharecast News) - Tullow Oil: Jefferies downgrades to hold with a target price of 222p.
Read more